All Treats, No Tricks!
I'd be hard-pressed to pick a favorite episode from the past month of Business of Biotech programming, but there's no doubt my interview with Treehill Partners founder Ali Pashazadeh would be a contender. Kind of ironic, given that he was a bit of a departure for us. Ali is not a biotech CEO or founder. He's a surgeon, investment banker, biotech board member, and consultant. And on episode 221, consult he did. Sure, he leaned a little bit close to pitchy here and there, but if he brought you the goodies he dropped on this hour+ episode over the phone, you'd pay dearly for the call.
Running neck-and-neck with the Pashazadeh episode is Profluent Chief Business Officer Hilary Eaton, Ph.D. on episode 220. It's another long one, and again, another departure (Profluent doesn't have a pipeline - yet), but holy smokes, she's good. Wherever you sit on the AI-in-biotech acceptance spectrum, from bullish to bearish, you'll come away enlightened and inspired by this episode.
If you haven't already, do yourself a solid and listen to what these two have to say.
In the meantime, here's a roundup of some fresh, hand-picked editorial content from my friends and colleagues in the Life Science Connect community. Matt Pillar, Business of Biotech host and chief editor, Bioprocess Online |
|
| | Biotech Beat | October 22, 2024 |
|
| ![]() | | We talk a lot about the proper cadence of hiring in biotech. As times, trends, and milestones change, so do executive and functional talent needs. And if you told me there's a biotech function more dynamic than that of regulatory affairs, you'd likely provoke an argument. In this Bioprocess Online exclusive, our friends Maggie Chan, Nora Hernandez, and Hilde Viroux at PA Consulting explore that dynamism. | READ NOW → |
|
![]() | | by ANNA ROSE WELCH | How do you scale down where there's no precedent? Biotechs are feverishy exploring how to apply a modality tested on a patient population of billions to indications with much, much smaller populations, and as Advancing RNA's Anna Rose Welch covers in this column, they're finding the exercise more difficult than it would seem. | READ NOW → |
|
| ![]() | | Rezolute CEO & Founder Nevan Charles Elam has graced the Business of Biotech with his presence on two occasions--way back on episode 39 and a mere 124 episodes later on episode 163. This month, Rezolute Head of Medical and Patient Affairs Davelyn Eaves Hood, MD, MBA, BCMAS lent her expertise to this exclusive Clinical Leader column on overcoming CUP (compassionat use program) challenges. | READ NOW → |
|
![]() | | by LOUIS GARGUILO | Over at Outsourced Pharma, Louis Garguilo has a knack for picking story topics and interviewing people that deliver practical advice to biotech builders. Like how to be sure the folks keeping vermin out of your manufacturing partners' facilities are doing their jobs. Biopharmaceutical manufacturing facilities maintenance and (insert any other industry) manufacturing facilities maintenance are not the same. | READ NOW → |
|
| | "If a company can't afford the entire cow, the fractional approach allows them to buy the steak instead, providing access to the expertise needed to avoid costly mistakes without over committing resources." | ― Allan Shaw, CFO & Special Advisor, Episode 223 |
|
| "Nothing in the pharmaceutical industry is traditional anymore. There's no 4,000 sales reps on the street selling feature/benefit/incentive. The commercial world is is turned on its head." | ― Mike Kelly, CEO, NervGen Pharma, Episode 222 |
|
| "The ultimate goal is not how you get there, it's just to get there ... If AI can help with that, I don't see why we should treat it any differently than any other tool that we have brought into the toolkit over the past decades of pharma." | ― Hilary Eaton, Ph.D., Chief Business Officer, Profluent Bio, Episode 220 |
|
| | | ![]() | Created exclusively for the leaders of new and emerging biopharma firms, the Business of Biotech podcast tackles organizational, funding, HR, regulatory, production and CMC considerations with insight from peer founders who have taken biologic therapies from an idea to clinical success. Check out our episode archive. | |
|
|
|
Ensure our newsletter reaches your inbox by following these whitelist instructions.
This newsletter is being sent to {{lead.Email Address}}. To cancel your subscription to the newsletter, please opt out. | © Copyright 2024 Vertmarkets, Inc. 5340 Fryling Rd Suite 100, Erie, PA 16510.
All rights reserved. All product names contained herein are the trademarks of their respective holders. |
|
|
|
|
